Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

27 janv. 2025 07h45 HE | Source: Kailera Therapeutics, Inc.

Kailera Therapeutics Appoints Jamie Coleman as Chief Commercial Officer

Kailera Therapeutics today announced the appointment of Jamie Coleman, former U.S. Brand Leader for Zepbound, as Chief Commercial Officer.
13 janv. 2025 08h00 HE | Source: Kailera Therapeutics, Inc.

Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics Report Positive Topline Data from 8 mg Dose of Phase 2 Obesity Trial of GLP-1/GIP Receptor Dual Agonist HRS9531

Kailera and Hengrui Pharma announced positive topline data from the 8 mg dose of Hengrui’s Phase 2 clinical trial of HRS9531, a GLP-1/GIP dual agonist.
10 nov. 2023 08h48 HE | Source: Research and Markets

Global Glucagon-like Peptide 1 (GLP-1) Market Soars to $18.75 Billion by 2023, Fueled by Increasing Healthcare Expenditure and Aging Population

Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Global Glucagon-like Peptide 1 (GLP-1) Market (by Product, Route of Administration, & Region): Insights and Forecast with Potential Impact of...